Presentation Information
[1BS04-01]"New Horizons in Protein Research: Ehime University PROS/Proteo-Interactome Analysis Platform (PRiME) and Cell-Free Sciences Co., Ltd.. (Ehime University Spin-off)
Ryo Morishita1, Tatsuya Sawasaki2 (1.CellFree Sciences Co., Ltd, 2.Proteo-Sicience Center, Ehime University)
CellFree Science Co., Ltd., an Ehime University spin-off venture, was established to commercialize and promote Wheat germ CellFree protein synthesis technology. This innovative system enables the direct conversion of genes from higher organisms into proteins and continues to be widely applied in the study of molecular mechanisms of life and the development of pharmaceuticals.
In this seminar, we will introduce a “new multi-sample screening” technology that combines the MaZiQ arrayⓇ—a protein bead array containing 20,000 human proteins, produced using Wheat germ CellFree synthesis technology optimized for multi-product, small-batch production—with proximity-dependent molecular labeling. This approach allows highly sensitive detection of both protein-protein and drug-protein interactions. Professor Sawasaki from Ehime University's Proteoscience Center will share an example of how this technology has been applied in his research.
Since fiscal year 2022, the Ehime University Proteoscience Center (PROS) has been designated as the “Proteo-Interactome Analysis Joint Research Center (PRiME),” a national hub for joint research and shared use. PROS and PRiME aim to advance the understanding of protein functions by developing analytical technologies for protein-protein interactions (the interactome), thereby supporting life science research nationwide. Protein-protein interactions have recently been recognized as critical not only in the regulation of major plant hormones but also in drug discovery, including the development of targeted protein degraders, and in fundamental biology.
This seminar will highlight ongoing technological developments at PROS and PRiME, including proximity biotinylation and human protein array technologies, and will discuss future directions for innovations in protein research
In this seminar, we will introduce a “new multi-sample screening” technology that combines the MaZiQ arrayⓇ—a protein bead array containing 20,000 human proteins, produced using Wheat germ CellFree synthesis technology optimized for multi-product, small-batch production—with proximity-dependent molecular labeling. This approach allows highly sensitive detection of both protein-protein and drug-protein interactions. Professor Sawasaki from Ehime University's Proteoscience Center will share an example of how this technology has been applied in his research.
Since fiscal year 2022, the Ehime University Proteoscience Center (PROS) has been designated as the “Proteo-Interactome Analysis Joint Research Center (PRiME),” a national hub for joint research and shared use. PROS and PRiME aim to advance the understanding of protein functions by developing analytical technologies for protein-protein interactions (the interactome), thereby supporting life science research nationwide. Protein-protein interactions have recently been recognized as critical not only in the regulation of major plant hormones but also in drug discovery, including the development of targeted protein degraders, and in fundamental biology.
This seminar will highlight ongoing technological developments at PROS and PRiME, including proximity biotinylation and human protein array technologies, and will discuss future directions for innovations in protein research
Comment
To browse or post comments, you must log in.Log in